Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation

The new anti-cancer drug zllascorb(2H) has shown promising activity in preclinical models. Its putative mechanism of action is reversible protein synthesis inhibition and longterm treatment is required. As a clinical treatment modality, long-term daily zilascorb(2H) infusions, as used in previous st